ADC Therapeutics (NYSE:ADCT) is one of the best multibagger penny stocks to buy right now. On December 4, Guggenheim analyst Michael Schmidt reaffirmed his Buy rating on ADC Therapeutics (NYSE:ADCT) and set a price target of $10.00. On December 3, RBC Capital reiterated an Outperform rating and$5.00 price target in response to interim Phase Ib data from the LOTIS-7 trial. RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development Data from the LOTIS-7 trial evaluating the safe ...